Full-Time

Sr Manager Regulatory and Clinical Affairs

Deadline 8/22/26
Thermo Fisher Scientific

Thermo Fisher Scientific

10,001+ employees

Supplies laboratory instruments, reagents, diagnostics

No salary listed

Birmingham, UK

In Person

Office-based in Birmingham, United Kingdom; on-site presence required.

Bachelor's, Master's

Category
Legal & Compliance (1)
Required Skills
Biostatistics
Risk Management

Get referred to Thermo Fisher Scientific

See people who can refer or advise you

Requirements
  • Bachelor’s degree in life sciences, clinical research, regulatory affairs, biomedical science, medicine, or a related field; advanced degree preferred.
  • 8+ years of experience with in vitro diagnostics, laboratory diagnostics, companion diagnostics, monitoring claims, or related diagnostic technologies; 10+ years preferred.
  • Experience with FDA submissions, including 510(k), De Novo, PMA supplements, Q-Submissions, or other regulatory interactions.
  • Experience with EU IVDR, clinical performance studies, performance evaluation reports, and/or global IVD regulatory requirements.
  • Experience managing or coordinating CROs, clinical sites, external laboratories, investigators, or clinical vendors.
  • Experience with biostatistics, clinical performance evaluation, analytical performance, risk management, and labeling/claims development.
Responsibilities
  • Develop and execute regulatory strategies for product claim expansions, new indications, expanded intended use, and new market access opportunities, in partnership with Regulatory Affairs leadership.
  • Recommend appropriate global regulatory pathways, submission requirements, evidence expectations, and agency interaction strategies for assigned programs.
  • Translate business priorities and product strategy into actionable regulatory plans, including timelines, risks, assumptions, and recommendations for decision points.
  • Lead and coordinate preparation of assigned regulatory submissions, responses to regulator questions, and supporting documentation packages, with oversight from Regulatory Affairs leadership as appropriate.
  • Assess product claims, intended use statements, labeling, promotional claims, and submission content to confirm they are supported by appropriate analytical, clinical, and scientific evidence.
  • Monitor evolving regulatory requirements and guidance relevant to clinical evidence, product claims, diagnostic performance, and market access, and communicate potential impact to project teams and leadership.
  • Develop and execute clinical evidence strategies to support regulatory submissions for product claim expansions, New Product Development (NPD), and new market access, in partnership with Regulatory Affairs, Medical Affairs, and Biostatistics stakeholders.
  • Develop, coordinate, and oversee assigned clinical study plans, protocols, study designs, statistical analysis plans, clinical performance evaluation strategies, and clinical study reports.
  • Manage assigned clinical operations resources and external partners to ensure studies are delivered on time, within scope, and in compliance with applicable regulatory, quality, ethical, and data integrity requirements.
  • Coordinate clinical data review, monitoring, cleaning, analysis, and interpretation to ensure outputs are submission-ready.
  • Collaborate with clinical sites, investigators, CROs, laboratories, and internal stakeholders to support effective study startup, execution, closeout, and reporting.
  • Confirm clinical study documentation supports regulatory submissions, clinical performance claims, risk-benefit assessments, and post-market obligations.
  • Identify clinical evidence gaps and recommend practical strategies to close those gaps.
  • Manage, coach, and develop assigned Regulatory Affairs and Clinical Affairs team members and/or project resources.
  • Lead cross-functional project teams responsible for claim expansion and clinical evidence programs.
  • Establish clear project plans, milestones, deliverables, owners, and escalation pathways.
  • Prepare and communicate program status, risks, decision recommendations, and trade-offs to leadership and governance forums.
  • Partner with Product Management and commercial stakeholders to evaluate and prioritize claim expansion opportunities based on customer need, regulatory feasibility, clinical evidence burden, cost, timeline, and business impact.
  • Partner with Quality and R&D to ensure regulatory and clinical requirements are integrated into design control, change control, risk management, and validation activities.
  • Influence stakeholders across functions and regions to support alignment, resolve issues, and maintain submission momentum.
Desired Qualifications
  • None
Thermo Fisher Scientific

Thermo Fisher Scientific

View

Thermo Fisher Scientific provides life sciences tools and services for research, healthcare, and industry. Its products include laboratory instruments, reagents, consumables, and software for activities like protein biology, PCR, sequencing, and bioprocessing. It differentiates itself with an end-to-end footprint across trusted brands and strong customer support and education, plus direct sales and promotions. Its goal is to help make the world healthier, cleaner, and safer by enabling discovery, diagnostics, and quality manufacturing across research institutions, healthcare providers, and government bodies.

Company Size

10,001+

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

1956

Get referred to Thermo Fisher Scientific

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $11.99 billion, with organic growth improving to 5%.
  • Management raised 2026 guidance to $47.4 billion-$48.1 billion after broad pharma and biotech recovery.
  • Clario's March 2026 acquisition adds clinical endpoint data, widening its biopharma services platform.

What critics are saying

  • CVE-2026-17583 lets attackers alter forensic DNA files, threatening trust in crime labs.
  • Thermo Fisher is closing Franklin and Weaverville plants through 2027, signaling operational churn.
  • Selling microbiology to Astorg strips $645 million revenue and weakens clinical consumables breadth.

What makes Thermo Fisher Scientific unique

  • Thermo Fisher won EXENT FDA clearance in 2025, expanding automated multiple-myeloma diagnostics.
  • Oncomine Dx Express returns NGS results in 24 hours, a speed edge for oncology.
  • GreenCool centrifuges and InstaFlux workflow deepen Thermo Fisher's workflow-locking sustainability pitch.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Fertility Treatment Support

Family Planning Benefits

Professional Development Budget

Conference Attendance Budget

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Company News

Yahoo Finance
Aug 10th, 2026
Thermo Fisher raises guidance as life sciences recovery broadens vs Danaher's uneven rebound

Thermo Fisher Scientific and Danaher, two major life sciences tools companies, both reported better-than-expected second-quarter results, but their recoveries show different trajectories. Thermo Fisher posted 10% revenue growth to $11.99 billion and 13% adjusted EPS growth to $6.03. The company raised guidance citing broad-based demand improvement across pharmaceutical and biotechnology markets. Its Life Sciences Solutions segment grew 13% year-over-year, whilst Analytical Instruments returned to growth after nearly two years of weak demand. Danaher's recovery remains more uneven, though it achieved high-single-digit adjusted EPS growth with improving core growth versus the previous quarter. Thermo Fisher's recovery appears more broad-based across multiple segments, suggesting greater durability. The company continues investing in product innovation, including new Orbitrap mass spectrometers.

NAPA
Aug 5th, 2026
Suit says faith foiled by fossil fuels in 401(k) funds.

Suit says faith foiled by fossil fuels in 401(k) funds. A new 401(k) suit alleges employment discrimination for refusing to offer investment options that don't invest in fossil fuels. A new 401(k) suit alleges employment discrimination in a refusal to offer investment options that don't invest in fossil fuels. The plaintiff here[i] is Dr. Andrew Hartley, a statistical science director at Thermo Fisher Scientific Inc., and the suit accuses his employer of discriminating against him and refusing to accommodate his religious beliefs in violation of Title VII[ii] and the New York State Human Rights Law. The suit asserts that he is a devout Christian and member of the United Methodist Church, and that he sincerely believes[iii] that investing his retirement money in "ecologically and socially destructive" fossil fuel companies violates his religious beliefs. The suit (Hartley v. Thermo Fisher Scientific Inc., case number 1:26-cv-01612, in the U.S. District Court for the Western District of New York) further asserts that due to the reality that Thermo Fisher's current equity-based retirement plan options maintain significant investments in fossil-fuel companies, he is "...forced to either compromise his religious beliefs or forego a significant component of his employer-provided benefit." The suit claims that Hartley requested that his employer "provide him with an accommodation that would allow him to partake of the benefits of his 401(k) plan in a manner consistent with his faith" - and that he "provided Thermo Fisher with a list of several funds that are frequently available on 401(k) menus and that are consistent with his beliefs, and asked that the company make one of them (or a similar fund of the company's choosing) available on the 401(k) plan menu." The suit notes that Thermo Fisher acknowledged receipt of the accommodation request "...but, despite multiple attempts to follow up and initiate negotiations, Thermo Fisher has failed to offer any accommodation or reason why such accommodation cannot be provided". Arguing that Hartley has been "subjected to persistent discrimination and denial of reasonable accommodations due to his religion," the suit says it wants to compel Thermo Fisher to "cease its unlawful discriminatory practices, implement effective policies to prevent religious discrimination, provide reasonable accommodations as required by law, and compensate him for the damages he has suffered as a result of Thermo Fisher's actions." Stay tuned. - Nevin E. Adams, JD [i] Hartley is represented by Kathleen Konopka of ClientEarth USA Inc. [ii] Title VII defines religion to include "all aspects of religious observance and practice, as well as belief," and requires an employer to accommodate its employees' religious beliefs "unless an employer demonstrates that he is unable to reasonably accommodate an employee's or prospective employee's religious observance or practice without undue hardship on the conduct of the employer's business." [iii] The suit asserts that "Dr. Hartley believes his Christian faith commands him to care for and steward the earth, and that actively investing in and profiting from fossil fuel companies whose work directly harms the earth, and its inhabitants, violates his religious obligations." Please log in or create a free account to comment on this article. Share to: Publish date: August 05, 2026 By: Sponsored by MFS

News4Hackers
Aug 4th, 2026
Critical vulnerability in DNA forensic software threatens 30 years of evidence.

Critical vulnerability in DNA forensic software threatens 30 years of evidence. Post Views: 14 Researchers have identified a significant security flaw in forensic software used by U.S. crime laboratories, risking DNA evidence from 1995 onward. Discovery of the vulnerability. Researchers have identified a significant security flaw in forensic software utilized by major U.S. crime laboratories, which could enable unauthorized modifications to DNA evidence dating back to 1995. The vulnerability, uncovered by a team of forensic and computer scientists, allows an AI-driven approach to alter digital representations of genetic data without detection. Impact on forensic evidence. Although the software vendor, Thermo Fisher Scientific, has not reported any confirmed breaches, the researchers emphasize that methods to detect such tampering remain elusive. A systems engineer demonstrated the exploit within an hour, gaining access to encrypted data. The potential for malicious actors to manipulate DNA profiles raises concerns about wrongful convictions or unjust acquittals. Broader implications. Experts highlight that forensic science has lagged in implementing robust security protocols compared to other sectors, resulting in inconsistent safeguards across more than 200 laboratories. Thermo Fisher Scientific has acknowledged the issue and is developing a software update incorporating digital signatures to ensure data integrity moving forward. Technical details of the exploit. The flaw specifically enables the manipulation of digital scans generated since 1995, leveraging machine learning techniques to introduce undetectable alterations. This capability could allow adversaries to introduce or remove genetic markers, undermining the reliability of forensic conclusions. Researchers noted that the exploit bypasses existing verification mechanisms, leaving no clear audit trail for investigators. Response and mitigation efforts. The discovery underscores broader challenges in securing legacy systems within the forensic sector, where rapid technological advancements have outpaced the adoption of modern cybersecurity practices. Thermo Fisher Scientific confirmed the vulnerability and stated that the upcoming update will include cryptographic validation to prevent unauthorized data modifications. However, the lack of immediate mitigation measures has prompted calls for urgent review of evidence-handling protocols. Long-Term concerns. The incident also raises questions about the long-term integrity of genetic databases, which contain records critical to both criminal investigations and civil cases. The findings align with growing concerns about the intersection of artificial intelligence and forensic science, as emerging technologies introduce new vectors for exploitation. Cybersecurity experts urge forensic institutions to prioritize proactive risk assessments and collaborate with software developers to address systemic vulnerabilities.

IT Security News
Aug 4th, 2026
Thermo Fisher DNA analysis software flaw lets attackers secretly alter test data.

Thermo Fisher DNA analysis software flaw lets attackers secretly alter test data. 2026-08-04 07:08 Thermo Fisher Scientific has released security updates for a high-severity flaw in its Applied Biosystems Human Identification (HID) software. This vulnerability could allow nearly undetectable manipulation of DNA test data files before analysis. The issue, tracked as CVE-2026-17583, carries a CVSS v4 score of 8.2 and affects .fsa and .hid file outputs used in forensic [...] Read the original article: Thermo Fisher Scientific has disclosed a high-severity security flaw affecting several of its Applied Biosystems Human Identification (HID) software... Secure email service August 3, 2026 In "Cyber Security News"

International Labmate Limited
Aug 4th, 2026
Natural refrigerant cooling for general purpose centrifuges.

Natural refrigerant cooling for general purpose centrifuges. 04 Aug, 2026 Thermo Fisher Scientific Thermo Fisher Scientific has expanded its centrifuge portfolio with the introduction of the Thermo Scientific(TM) X2 and S2 Series General Purpose Centrifuges, bringing natural refrigerant cooling technology to smaller-capacity systems for medical research, biopharma and clinical laboratories. Offering capacities of up to 1.6 litres per run, the new models combine a compact footprint with the performance, safety and ergonomic features found in the larger X4 and S4 Series. The systems are designed to support a wide range of laboratory workflows where reliable sample separation and efficient use of space are essential. With the launch of the X2 and S2 Series, Thermo Fisher Scientific says it is the first manufacturer to offer a complete portfolio of refrigerated centrifuges using natural refrigerants. Incorporating Thermo Scientific(TM) GreenCool(TM) Technology, the systems use a refrigerant with a Global Warming Potential (GWP) of just three, helping laboratories reduce environmental impact while complying with current European and US F-gas regulations. The centrifuges are also more energy efficient than previous models and are manufactured at a certified zero-waste facility powered entirely by renewable electricity. Designed for versatility, the X2 and S2 Series are available in both refrigerated and ventilated configurations, with general laboratory and IVD/medical device versions to suit different applications. Users can choose from a wide selection of fixed-angle and swinging-bucket rotors, including Thermo Scientific(TM) Fiberlite(TM) carbon fibre options, enabling the systems to support applications ranging from cell culture and molecular biology to clinical diagnostics, cell and gene therapy, bioproduction and quality control. The centrifuges also incorporate features to simplify day-to-day operation. Thermo Scientific(TM) Auto-Lock(TM) Rotor Exchange allows rotor changes in less than three seconds, while ClickSeal(TM) biocontainment lids enable secure one-handed operation. Together with enhanced temperature control and an extended refrigerated operating range down to -20°C, the new systems are designed to improve productivity while supporting more sustainable laboratory workflows. More information online